The presence of ECV in the circulation likely contributes to the increased formation of vimentin antibodies, as observed in allograft rejection [124], syngeneic cardiac transplant rejection [125], pulmonary fibrosis [126], systemic lupus erythematosus [127], Behçet’s disease (BD) [128], and the generation of citrullinated vimentin in rheumatoid arthritis [129]. This evidence concerns the gene VIM and pulmonary fibrosis.